Pseudomonas aeruginosa: Burn infection, treatment and antibacterial resistance

Iranian Red Crescent Medical Journal

Volumn 11, Issue 3, 2009, Pages 244-253

  Japoni, Aziz ^a   Farshad, S ^a   Alborzi, A ^a  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Integron; Multidrug resistance; Plasmid; Pseudomonas aeruginosa

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; COLISTIN; ELASTASE; EXOENZYME S; EXOTOXIN; EXOTOXIN A; FC RECEPTOR; GENTAMICIN; MAFENIDE ACETATE; METALLO BETA LACTAMASE; MONOBACTAM DERIVATIVE; NYSTATIN; PENICILLIN G; PHOSPHOLIPASE C; PROTEINASE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SILVER NITRATE; SULFADIAZINE SILVER; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; BURN INFECTION; BURN PATIENT; CREAM; DISEASE SEVERITY; HUMAN; LEUKOPENIA; METABOLIC ACIDOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; OINTMENT; PREVALENCE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; REVIEW; TOPICAL TREATMENT; WOUND DRESSING; WOUND HEALING IMPAIRMENT;

EID: 67849090303     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (105)

1. Krieg, Noel Bergey's Manual of Systematic Bacteriology, Volume 1. Baltimore: Williams & Wilkins, 1984.
2. Anzai Y, Kim H, Park JY, Wakabayashi H, Oyaizu H. Phylogenetic affiliation of the pseudomonads based on 16S rRNA sequence. Int J Syst Evol Microbiol 2000;50:1563-89. [1093 9664]
3. Franzetti F, Cernuschi M, Esposito R, Moroni M. Pseudomonas infections in patients with AIDS and AIDS related complex. J Intern Med 1992;231:437-43. [1588272]
4. Kielhofner M, Atmar RL, Hamill RJ, Musher DM. Life-threatening Pseudomonas aeruginosa infections inpatients with human immunodeficiency virus infection. Clin Infect Dis 1992; 14:403-11. [1554824]
5. Bendig JW, Kyle PW, Giangrande PL, Samson DM, Azadian BS. Two neutropenic patients with multiple resistant Pseudomonas aeruginosa septicaemia treated with ciprofloxacin. J R Soc Med 1987;80 :316-7. [3112380]
6. Chitkara YK, Feierabend TC. Endogenous and exogenous infection with Pseudomonas aeruginosa in a burns unit. Int Surg 1981; 66:237-40. [6797982]
7. Phillips LG, Heggers JP, Robson MC, Boertman JA, Meltzer T, Smith DJ Jr. The effect of endogenous skin bacteria on burn wound infection. Ann Plast Surg 1989;23:35-8. [2764460] [doi:10.1097/ 00000637-198907000-00007]
8. Hsueh PR, Teng LJ, Yang PC. Chen YC, Ho SW, Luh KT. Persistence of a multidrug-resistant Pseudomonas aeruginosa clone in an intensive care burn unit. J Clin Microbiol 1998;36:1347-51. [9574703]
9. Japoni A, Farshad S, Alborzi A, Kalani M, Mohamadzadegan R. Comparison of arbitrarily primed-polymerase chain reaction and plasmid profiles typing of Pseudomonas aeruginosa strains from burn patients and hospital environment. Saudi Med J 2007;28:899-903. [17530107]
10. Rahme LG, Stevens EJ, Wolfort SF, Shao J, Tompkins RG, Ausubel FM. Common virulence factors for bacterial pathogenicity in plants and animals. Science 1995;268: 1899-902. [76 04262] [doi:10.1126/science.7604262]
11. Sato H, Okinaga K, Saito H. Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infection. Microbiol Immunol 1988;32:131-9. [2897617]
12. Pavlovskis OR, Wretlind B. Assessment of protease (elastase) as a Pseudomonas aeruginosa virulence factor in experimental mouse burn infection. Infect Immun 1979;24:181-7. [110690]
13. Bejarano PA, Langeveld JP, Hudson BG, Noelken ME. Degradation of basement membranes by Pseudomonas aeruginosa elastase. Infect Immun 1989;57:3783-7. [2509368]
14. Kharazmi A, Nielsen H. Inhibition of human monocyte chemotaxis and chemiluminescence by Pseudomonas aeruginosa elastase. APMIS 1991;99:93-5. [1899578]
15. Rumbaugh KP, Griswold JA, Hamood AN. Contribution of the regulatory gene lasR to the pathogenesis of Pseudomonas aeruginosa infection of burned mice. J Burn Care Rehabil 1999;20:42-9. [9934636]
16. Rumbaugh KP, Griswold JA, Iglewski BH, Hamood AN. Contribution of quorum sensing to the virulence of Pseudomonas aeruginosa in burn wound infections. Infect Immun 1999;67:5854-62. [10531240]
17. Ostroff RM, Vasil ML. Identification of a new phospholipase C activity by analysis of an insertional mutation in the hemolytic phospholipase C structural gene of Pseudomonas aeruginosa. J Bacteriol 1987; 169:4597-601. [2820937]
18. Sokol PA. Surface expression of ferripyochelin-binding protein is required for virulence of Pseudomonas aeruginosa. Infect Immun 1987; 55:2021-5. [3114141]
19. Goldberg JB, Coyne MJ Jr, Neely AN, Holder IA. A virulence of a Pseudomonas aeruginosa algC mutant in a burned-mouse model of infection. Infect Immun 1995;63: 4166-9. [7558335]
20. Nicas TI, Iglewski BH. Contribution of exoenzyme S to the virulence of Pseudomonas aeruginosa. Antibiot Chemother 1985;36:40-8. [2988426]
21. Bowen-Jones JR, Coovadia YM, Bowen-Jones EJ. Infection control in a Third World burn facility. Burns 1990;16:445-8. [2073344] [doi:10.1016/0305-4179(90)90075-8]
22. Felts AG, Giridhar G, Grainger DW, Slunt JB. Efficacy of locally delivered polyclonal immunoglobulin against Pseudomonas aeruginosa infection in a murine burn wound model. Burns 1999;25:415-23. [10439150] [doi:10.1016/S0305-4179(99)00017-0]
23. Jeyapaul J, Mehta LN, Arora S, Antia NH. Fc and complement receptor integrity of polymorphonuclear (PMN) cells following thermal injury. Burns Incl Therm Inj 1984; 10:387-95. [6434163] [doi:10.1016/0305-4179(84)90077-9]
24. Deitch EA, Dobke M, Baxter CR. Failure of local immunity. A potential cause of burn wound sepsis. Arch Surg 1985;120:78-84. [3917665]
25. Engel J, Balachandran P. Role of Pseudomonas aeruginosa type III effectors in disease. Curr Opin Microbiol 2009;12:61-6. [19168385] [doi:10.1016/j.mib.2008.12.007]
26. Deng Q, Zhang Y, Barbieri JT. Intracellular trafficking of Pseudomonas ExoS, a type III cytotoxin. Traffic 2007; 8:1331-45. [17714437] [doi:10.1111/j.1600-0854.2007.00626.x]
27. Jørgensen R, Wang Y, Visschedyk D, Merrill AR. The nature and character of the transition state for the ADP-ribosyltransferase reaction. EMBO Rep 2008;9:802-9. [18583986] [doi:10.1038/ embor.2008.90]
28. Kohno K, Uchida T, Mekada E, Okada Y. Characterization of diphtheria-toxin-resistant mutants lacking receptor function or containing nonribosylatable elongation factor 2. Somat Cell Mol Genet 1985;11:421-31. [3862242] [doi:10.1007/BF01534836]
29. Wolf P, Elsässer-Beile U. Pseudomonas exotoxin A: from virulence factor to anti-cancer agent. Int J Med Microbiol 2009; 299:161-76. [18948059] [doi:10.1016/j.ijmm.2008.08.003]
30. Moller PC, Evans MJ, Fader RC, Henson LC, Rogers B, Heggers JP. The effect of anti-exotoxin A on the adherence of Pseudomonas aeruginosa to hamster tracheal epithelial cells in vitro. Tissue Cell 1994; 26:181-8. [8023323] [doi:10.1016 /0040-8166(94)90093-0]
31. Agnihotri N, Gupta V, Joshi RM. Aerobic bacterial isolates from burn wound infections and their antibiograms: five-year study. Burns 2004;30:241-3. [15082351] [doi:10.1016/j.burns.2003.11.010]
32. Erol S, Altoparlak U, Akcay MN, Celebi F, Parlak M. Changes of microbial flora and wound colonization in burned patients. Burns 2004; 30:357-61. [15145194] [doi:10.1016/j.burns.2003.12.013]
33. Pedersen SS, Koch C, Hoiby N, Rosendal K. An epidemic spreadof multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17:505-16. [3086274] [doi:10.1093/jac/ 17.4.505]
34. Cheng K, Smyth RL, Govan JR, Doherty C, Winstanley C, Denning N, Heaf DP, van Saene H, Hart CA. Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic. Lancet 1996; 348:639-42. [8782753] [doi:10.1016/S0140-6736(96)05169-0]
35. Lechtzin N, John M, Irizarry R, Merlo C, Diette GB, Boyle MP. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006;73:27-33. [16113513] [doi:10.1159/000087686]
36. Lang AB, Rudeberg A, Schoni MH, Que JU, Furer E, Schaad UB. Vaccination of cystic fibrosis patients against Pseudomonas aeruginosa reduces the proportion of patients infected and delays time to infection. Pediat Infect Dis J 2004;23:504-10. [15194830] [doi:10.1097/01.inf.0000129688.50588.ac]
37. Pennington JE, Reynolds HY, Wood RE, Robinson RA, Levine AS. Use of a Pseudomonas aeruginosa vaccine in patients with acute leukemia and cystic fibrosis. Am J Med 1975;58:629-36. [805535] [doi:10.1016/ 0002-9343(75)90498-2]
38. Manafi A, Kohanteb J, Mehrabani D, Japoni A, Amini M, Naghmachi M, Zaghi AH, Khalili N. Active immunization using exotoxin A confers protection against Pseudomonas aeruginosa infection in a mouse burn model. BMC Microbiol 2009;9: 23. [19183501] [doi:10.1186/ 1471-2180-9-23]
39. Cripps AW, Peek K, Dunkley M, Vento K, Marjason JK, McIntyre ME, Sizer P, Croft D, Sedlak-Weinstein L. Safety and immunogenicity of an oral inactivated whole-cell Pseudomonas aeruginosa vaccine administered to healthy human subjects. Infect Immun 2006;74:968-74. [16428742] [doi:10.1128/IAI.74.2.968-974.2006]
40. Döring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 2008;26: 1011-24. [18242792] [doi:10.1016/ j.vaccine.2007.12.007]
41. Heggers JP, Hawkins H, Edgar P, Villarreal C, Herndon DN. Treatment of infections in burns. In: Herndon DN. Total burn care. WB Saunders, London, England. 2002; pp 120-169.
42. Murphy KD, Lee JO, Herndon DN. Current pharmacotherapy for the treatment of severe burns. Expert Opin Pharmacother 2003;4:369-84. [12614189] [doi:10.1517/14656566.4.3.369]
43. Altoparlak U, Erol S, Akcay MN, Celebi F, Kadanali A. The time related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns 2004;30:660-4. [15475138] [doi:10.1016/j.burns.2004.03.005]
44. Elliott TS, Lambert PA. Antibacterial resistance in the intensive care unit: mechanisms and management. Br Med Bull 1999; 55:259-76. [10695090] [doi:10.1258/0007142991902240]
45. Namias N, Samiian L, Nino D, Shirazi E, O'Neill K, Kett DH, Ginzburg E, McKenney MG, Sleeman D, Cohn SM. Incidence and susceptibility of pathogenic bacteria vary between intensive care units within a single hospital: implications for empiric antibiotic strategies. J Trauma 2000;49:638-45. [11038080] [doi:10.1097/00005373-200010000-00010]
46. Lansdown AB. Silver. 1. Its antibacterial properties and mechanism of action. J Wound Care 2002;11:125-30. [11998592]
47. Lansdown AB, Williams A, Chandler S, Benfield S. Silver absorption and antibacterial efficacy of silver dressings. J Wound Care 2005;14:155-60. [15835225]
48. Lansdown AB. Silver. 2. Toxicity in mammals and how its products aid wound repair. J Wound Care 2002;11:173-7. [12055941]
49. Boyce ST, Supp AP, Swope VB, Warden GD. Topical sulfamylon reduces engraftment of cultured skin substitutes on athymic mice. J Burn Care Rehabil 1990;20:33-6. [9934634]
50. Cooper ML, Boyce ST, Hansbrough JF, Foreman TJ, Frank DH. Cytotoxicity to cultured human keratinocytes of topical antimicrobial agents. J Surg Res 1990;48:190-5. [2314091] [doi:10.1016/ 0022-4804(90)90212-K]
51. Atiyeh BS, Dham R, Kadry M, Abdallah AF, Al-Oteify M, Fathi O, Samir A. Benefit-cost analysis of moist exposed burn ointment. Burns 2002;28:659-63. [12417161] [doi:10.1016/S0305-4179(02)00075-X]
52. Atiyeh BS, Ioannovich J, Magliacani Masellis GM, Costagliola M, Dham R, Al-Farhan M. Efficacy of moist exposed burn ointment in the management of cutaneous wounds and ulcers: a multicenter pilot study. Ann Plast Surg 2002;48:226-7. [11910244] [doi:10.1097/ 00000637-200202000-00032]
53. Atiyeh, BS, El-Musa KA, Dham R. Scar quality and physiologic barrier function restoration after moist and moist-exposed dressings of partial-thickness wounds. Dermatol Surg 2003;29:14-20. [12534506] [doi:10.1046/j.1524-4725.2003.29002.x]
54. Klasen HJ. A historical review of the use of silver in the treatment of burns. II. Renewed interest for silver. Burns 2000; 26:131-8. [10716355] [doi:10.1016/S0305-4179(99)00116-3]
55. Herruzo-Cabrera R, Garcia-Torres V, Rey-Calero J, Vizcaino-Alcaide MJ. Evaluation of the penetration strength, bactericidal efficacy and spectrum of action of several antimicrobial creams against isolated microorganisms in a burn centre. Burns 1992;18:39-44. [1558672] [doi:10.1016/0305-4179(92)90118-E]
56. Stefanides MM Sr, Copeland CE, Kominos SD, Yee RB. In vitro penetration of topical antiseptics through eschar of burn patients. Ann Surg 1976;183:358-64. [1267492]
57. MacMillan BG, Hill EO, Altemeier WA. Use of topical silver nitrate, mafenide, and gentamicin in the burn patient. A comparative study. Arch Surg 1967;95:472-81. [4962314]
58. Heggers JP, Robson MC, Herndon DN, Desai MH. The efficacy of nystatin combined with topical microbial agents in the treatment of burn wound sepsis. J Burn Care Rehabil 1989;10:508-11. [2600098] [doi:10.1097/00004630-198911000-00009]
59. Wright JB, Lam K, Hansen D, Burrell RE. Efficacy of topical silver against fungal burn wound pathogens. Am J Infect Control 1999; 27:344-50. [10433674] [doi:10.1016/S0196-6553(99)70055-6]
60. Choban, PS, Marshall WJ. Leukopenia secondary to silver sulfadiazine: frequency, characteristics and clinical consequences. Am Surg 1987;53:515-7. [3631764]
61. Fuller FW, Engler PE. Leukopenia in non-septic burn patients receiving topical 1% silver sulfadiazine cream therapy: a survey. J Burn Care Rehabil 1988;9:606-9. [3220867] [doi:10.1097/ 00004630-198811000-00006]
62. Pirnay JP, De Vos D, Cochez C, Bilocq F, Pirson J, Struelens M, Duinslaeger L, Cornelis P, Zizi M, Vanderkelen A. Molecular epidemiology of Pseudomonas aeruginosa colonization in a burn unit: persistence of a multidrug-resistant clone and a silver sulfadiazine-resistant clone. J Clin Microbiol 2003;41:1192-202. [12624051] [doi:10.1128/JCM.41.3.1192-1202.2003]
63. Garner JP, Heppell PS. The use of Flammacerium in British Burns Units. Burns 2005;31:379-82. [15774299] [doi:10.1016/ j.burns.2004.12.001]
64. Garner JP, Heppell PS. Cerium nitrate in the management of burns. Burns 2005;31:539-47. [15955636] [doi:10.1016/ j.burns.005.01.014]
65. Falcone PA, Harrison HN, Sowemimo GO, Reading GP. Mafenide acetate concentrations and bacteriostasis in experimental burn wounds treated with a three-layered laminated mafenide-saline dressing. Ann Plast Surg 1980;5:266-9. [6985504] [doi:10.1097/ 00000637-198010000-00003]
66. Boyce ST, Supp AP, Swope VB, Warden GD. Topical sulfamylon reduces engraftment of cultured skin substitutes on athymic mice. J Burn Care Rehabil 1999;20:33-6. [9934634]
67. Dunn K, Edwards-Jones V. The role of Acticoat with nanocrystallinesilver in the management of burns. Burns 2004;30:S1-9. [15327800] [doi:10.1016/S0305-4179(04)90000-9]
68. Tredget EE, Shankowsky HA, Groeneveld A, Burrell R. A matched-pair, randomized study evaluating the efficacy and safety of Acticoat silver-coated dressing for the treatment of burn wounds. J Burn Care Rehabil 1998;19:531-7. [9848045] [doi:10.1097/ 00004630-199811000-00013]
69. Yin HQ, Langford R, Burrell RE. Comparative evaluation of the antimicrobial activity of ACTICOAT antimicrobial barrier dressing. J Burn Care Rehabil 1999;20:195-200. [10342470] [doi:10.1097/ 00004630-199905000-00006]
70. Heggers, J, Goodheart RE, Washington J, McCoy L, Carino E, Dang T, Edgar P, Maness C, Chinkes D. Therapeutic efficacy of three silver dressings in an infected animal model. J Burn Care Rehabil 2005; 26:53-6. [15640735] [doi:10.1097/01.BCR.0000150298.57472.26]
71. Vasishta R, Saxena M, Chhibber S. Contribution of silver ion resistance to the pathogenicity of Pseudomonas aeruginosa with special reference to burn wound sepsis. Folia Microbiol (Praha) 1991; 36:498-501. [1821876] [doi:10.1007/BF02884072]
72. Daikos GL, Lolans VT, Jackson GG. Alterations in outer membrane proteins of Pseudomonas aeruginosa associated with selective resistance to quinolones. Antimicrob Agents Chemother 1988;32:785-7. [3134852]
73. Bridges K, Kidson A, Lowbury EJ, Wilkins MD. Gentamicin and silver-resistant pseudomonas in a burns unit. Br Med J 1979; 1:446-9. [10 6914] [doi:10.1136/bmj.1.6161.446]
74. Hendry AT, Stewart IO. Silver-resistant Enterobacteriaceae from hospital patients. Can J Microbiol 1979;25:915-21. [526888]
75. Rosenkranz HS, Coward JE, Wlodkowski TJ, Carr HS. Properties of silver sulfadiazine resistant Enterobacter cloacae. Antimicrob Agents Chemother 1974;5:199-201. [4840432]
76. Japoni A, Hayati M, Farshad SH, Abbasia SA. In vitro Susceptibility of Pseudomonas aeruginosa Isolated from a Burn Center to Silver Sulfadiazine and Silver Nitrate in Shiraz, South of Iran. Iran J Med Sci 2005;30:63-7.
77. Jalal S, Wretlind B. Mechanisms of quinolone resistance in clinical strains of Pseudomonas aeruginosa. Microb Drug Resist 1998; 4:257-61. [9988043] [doi:10.1089/mdr.1998.4.257]
78. Livermore DM. beta-Lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-84. [8665470]
79. Poole K. Multidrug efflux pumps and antimicrobial resistance in Pseudomonas aeruginosa and related organisms. J Mol Microbiol Biotechnol 2001;3:255-64. [11321581]
80. Masuda N, Sakagawa E, Ohya S, Gotoh N, Tsujimoto H, Nishino T. Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXYoprM efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000; 44:3322-7. [11083635] [doi:10.1128/AAC.44.12.3322-3327.2000]
81. Woodruff WA, Hancock RE. Construction and characterization of Pseudomonas aeruginosa protein F-deficient mutants after in vitro and in vivo insertion mutagenesis of the cloned gene. J Bacteriol 1988;170: 2592-8. [2836364]
82. Mayer KH. Review of epidemic aminoglycoside resistance world wide. Am J Med 1986;80:56-64. [3089005] [doi:10.1016/ 0002-9343(86)90480-8]
83. Studemeister AE, Quinn JP. Selective imipenem resistance in Pseudomonas aeruginosa associated with diminished outer membrane permeability. Antimicrob Agents Chemother 1988;32:1267-8. [2461164]
84. Ochs MM, McCusker MP, Bains M, Hancock RE. Negative regulation of the Pseudomonas aeruginosa outer membrane porin OprD selective for imipenem and basic amino acids. Antimicrob Agents Chemother 1999; 43:1085-90. [10223918]
85. Lee A, Mao W, Warren MS, Mistry A, Hoshino K, Okumura R, Ishida H, Lomovskaya O. Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol 2000; 182:3142-50. [10809693] [doi:10.1128/JB.182.11.3142-3150.2000]
86. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288: 1251-4. [10818002] [doi:10.1126/science.288.5469.1251]
87. Vahaboglu H, Ozturk R, Aygun G, G, Coşkunkan F, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Otkun M. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41:2265-9. [9333059]
88. Naas T, Nordmann P. OXA-type β-lactamases. Curr Pharm Des 1999; 5:865-79. [10539993]
89. Poirel L, Girlich D, Naas T, Nordmann P. OXA-28, an extended-spectrum variant of OXA-10 β-lactamase from Pseudomonas aeruginosa and its plasmid and integral in located gene. Antimicrob Agents Chemother 2001; 45:447-53. [11158739] [doi:10.1128/AAC.45.2. 447-453.2001]
90. Danel F, Hall LM, Duke B, Gur D, Livermore DM. OXA-17, a further extended-spectrum variant of OXA-10 β-lactamase, isolated from Pseudomonas aeruginosa. Antimicrob Agents Chemother 1999; 43:1362-6. [10348753]
91. Livermore DM, Woodford N. Carbapenemases: a problem in waiting? Curr Opin Microbiol 2000;3: 489-95. [11050448] [doi:10.1016/ S1369-5274(00)00128-4]
92. Senda K, Arakawa Y, Nakashima K, Ito H, Ichiyama S, Shimokata K, Kato N, Ohta M. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems. Antimicrob Agents Chemother 1996; 40:349-53. [8834878]
93. Gibb AP, Tribuddharat C, Moore RC, Louie TJ, Krulicki W, Livermore DM, Palepou MF, Woodford N. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new blaIMP allele, blaIMP-7. Antimicrob Agents Chemother 2002; 46:255-8. [11751148] [doi:10.1128/AAC.46.1.255-258.2002]
94. Lauretti L, Riccio ML, Mazzariol A, Lauretti L, Fontana R, Rossolini GM. Cloning and characterization of blaVIM, a new integrin-borne metallo-β-lactamase gene from a Pseudomonas aeruginosa clinical isolate. Antimicrob Agents Chemother 1999; 43:1584-90. [10390207]
95. Arakawa Y, Murakami M, Suzuki K, Ito H, Wacharotayankun R, Ohsuka S, Kato N, Ohta M. A novel integron-like element carrying the metallo-β-lactamase gene blaIMP. Antimicrob Agents Chemother 1995; 39:1612-5. [7492116]
96. Japoni A, Alborzi A, Kalani M, Nasiri J, Hayati M, Farshad S. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran. Burns 2006;32:343-7. [16527415] [doi:10.1016/ j.burns.2005.10.017]
97. Ekrami A, Kalantar E. Bacterial infections in burn patients at a burn hospital in Iran. Indian J Med Res 2007;126:541-4. [18219081]
98. Rastegar Lari A, Bahrami Honar H, Alaghehbandan R. Pseudomonas infections in Tohid Burn Center, Iran. Burns 1998; 24:637-41. [9882062] [doi:10.1016/S0305-4179(98) 00090-4]
99. Estahbanati HK, Kashani PP, Ghanaatpisheh F. Frequency of Pseudomonas aeruginosa serotypes in burn wound infections and their resistance to antibiotics. Burns 2002;28:340-8. [12052372] [doi:10.1016/ S0305-4179(02)00024-4]
100. Tsakris A, Pournaras S, Woodford N, Palepou MF, Babini GS, Douboyas J, Livermore DM. Outbreak of infections caused by Pseudomonas aeruginosa producing VIM-1 carbapenemase in Greece. J Clin Microbiol 2000;38:1290-2. [10699045]
101. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 1999;43:1379-82. [10348756]
102. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001;47:247-50. [11222556] [doi:10.1093/ jac/47.3.247]
103. Levin AS, Barone AA, Penco J, MV, Marinho IS, Arruda EA, Manrique EI, Costa SF. Intravenous colistin as therapy for nosocomial infections caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Clin Infect Dis 1999;28:1008-11. [10452626] [doi:10.1086/514732]
104. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, Lee M, Blais J, Cho D, Chamberland S, Renau T, Leger R, Hecker S, Watkins W, Hoshino K, Ishida H, Lee VJ. Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother 2001;45:105-16. [11120952] [doi:10.1128/AAC.45.1.105-116.2001]
105. Hammond GG, Huber JL, Greenlee ML, Laub JB, Young K, Silver LL, Balkovec JM, Pryor KD, Wu JK, Leiting B, Pompliano DL, Toney JH. Inhibition of IMP-1 metallo-β-lactamase and sensitization of IMP-1-producing bacteria by thioester derivatives. FEMS Microbiol Lett 1999; 179:289-96. [10518728]